173 related articles for article (PubMed ID: 8637384)
21. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal.
Pandey B; Shrestha K; Lewis J; Hawksworth RA; Walker SL
Trop Doct; 2007 Jul; 37(3):162-3. PubMed ID: 17716505
[TBL] [Abstract][Full Text] [Related]
22. Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects.
Gonçalves Hde S; Pontes MA; Bührer-Sékula S; Cruz R; Almeida PC; Moraes ME; Penna GO
Mem Inst Oswaldo Cruz; 2012 Dec; 107 Suppl 1():74-8. PubMed ID: 23283457
[TBL] [Abstract][Full Text] [Related]
23. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
[TBL] [Abstract][Full Text] [Related]
24. Ofloxacin-Containing Multidrug Therapy in Ambulatory Leprosy Patients: A Case Series.
Faust L; Klowak M; MacRae C; Kopalakrishnan S; Showler AJ; Boggild AK
J Cutan Med Surg; 2021; 25(1):45-52. PubMed ID: 32869655
[TBL] [Abstract][Full Text] [Related]
25. Dapsone induced pulmonary eosinophilia without cutaneous allergic manifestations--an unusual encounter--a case report.
Arunthathi S; Raju S
Acta Leprol; 1998; 11(1):3-5. PubMed ID: 9693685
[TBL] [Abstract][Full Text] [Related]
26. Dapsone syndrome with acute renal failure during leprosy treatment: case report.
Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Fontes CJ
Braz J Infect Dis; 2005 Feb; 9(1):84-6. PubMed ID: 15947852
[TBL] [Abstract][Full Text] [Related]
27. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
Becx-Bleumink M; Berhe D
Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
[TBL] [Abstract][Full Text] [Related]
28. Dapsone induced eosinophilic pneumonia.
Adar T; Tayer-Shifman O; Mizrahi M; Tavdi S; Barak O; Shalit M
Eur Ann Allergy Clin Immunol; 2012 Jun; 44(3):144-6. PubMed ID: 22905598
[TBL] [Abstract][Full Text] [Related]
29. Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL south Indian patients: a five-year report.
Thomas A; Balakrishnan A; Nagarajan M; Prabhakar R; Tripathy SP; Christian M; Somasundaram PR
Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):273-80. PubMed ID: 2198314
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
[TBL] [Abstract][Full Text] [Related]
31. Two microbiological relapses in a patient with lepromatous leprosy.
Chakma JK; Girdhar A; Natrajan M; Kumar A; Girdhar BK
Lepr Rev; 2008 Sep; 79(3):331-4. PubMed ID: 19009984
[TBL] [Abstract][Full Text] [Related]
32. Fatal reaction to dapsone during treatment of leprosy.
Frey HM; Gershon AA; Borkowsky W; Bullock WE
Ann Intern Med; 1981 Jun; 94(6):777-9. PubMed ID: 7235421
[TBL] [Abstract][Full Text] [Related]
33. Joint chemotherapy trials in lepromatous leprosy conducted in Thailand, the Philippines, and Korea.
Cellona RV; Fajardo TT; Kim DI; Hah YM; Ramasoota T; Sampattavanich S; Carrillo MP; Abalos RM; dela Cruz EC; Ito T
Int J Lepr Other Mycobact Dis; 1990 Mar; 58(1):1-11. PubMed ID: 2181040
[TBL] [Abstract][Full Text] [Related]
34. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
Jing Z; Zhang R; Zhou D; Chen J
Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
[TBL] [Abstract][Full Text] [Related]
35. Th17 Response of Borderline-Lepromatous Leprosy Inhibits Rash Manifestation of Dapsone Hypersensitivity Syndrome: Case Report.
de Nardo Vanzela T; Bernardes Filho F; Wambier CG; Faria FM; Foss NT; Frade MAC
Am J Dermatopathol; 2018 Mar; 40(3):205-208. PubMed ID: 28937434
[TBL] [Abstract][Full Text] [Related]
36. Modification of multidrug treatment of leprosy in Vanuatu.
Reeve PA; Ala J; Hall JJ
Int J Lepr Other Mycobact Dis; 1992 Dec; 60(4):655-6. PubMed ID: 1299719
[No Abstract] [Full Text] [Related]
37. Hematological alterations in lepromatous leprosy: A cross-sectional observational study.
Gupta B; Gupta S; Chaudhary M; Raj AT; Awan KH; Patil S
Dis Mon; 2020 Jul; 66(7):100919. PubMed ID: 31796205
[TBL] [Abstract][Full Text] [Related]
38. Dapsone hypersensitivity syndrome among leprosy patients in China.
Tian W; Shen J; Zhou M; Yan L; Zhang G
Lepr Rev; 2012 Dec; 83(4):370-7. PubMed ID: 23614255
[TBL] [Abstract][Full Text] [Related]
39. T-cell plasticity of dapsone and DRESS.
Markova A; Duquesnoy R; Levis W
J Drugs Dermatol; 2014 Jan; 13(1):12-3. PubMed ID: 24385113
[No Abstract] [Full Text] [Related]
40. Implementation of genetic screening test to reduce the incidence of dapsone hypersensitivity syndrome among patients with leprosy in Papua, Indonesia: a study protocol.
Krismawati H; Ferdiana A; Irwanto A; Budiawan T; Imaniar C; Wahyuni T; Singh P; Mieras L; Pongtiku A
BMJ Open; 2022 May; 12(5):e057173. PubMed ID: 35545382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
